MX2017008072A - Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa. - Google Patents

Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa.

Info

Publication number
MX2017008072A
MX2017008072A MX2017008072A MX2017008072A MX2017008072A MX 2017008072 A MX2017008072 A MX 2017008072A MX 2017008072 A MX2017008072 A MX 2017008072A MX 2017008072 A MX2017008072 A MX 2017008072A MX 2017008072 A MX2017008072 A MX 2017008072A
Authority
MX
Mexico
Prior art keywords
pi3k
mtor
formulations
inhibitor
intravenous administration
Prior art date
Application number
MX2017008072A
Other languages
English (en)
Inventor
Richard Back Kevin
Cram Michael
James Harper Aidan
James Huang W
Richard Lillis Jonathan
Michael Lukas Timothy
Luthra Sumit
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2017008072A publication Critical patent/MX2017008072A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con una formulación farmacéutica acuosa que comprende 1-(4-{[4-(dimetilamino)piperidin -1-il]carbonil}enil)-3-[4-(4,6-dimorfolin-4-il-1,3,5-triazin-2-iI )enil]urea, o una sal farmacéuticamente aceptable de la misma, que es una solución transparente; tal formulación es particularmente adecuada para administración intravenosa o parenteral a un paciente.
MX2017008072A 2014-12-17 2015-12-10 Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa. MX2017008072A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462093060P 2014-12-17 2014-12-17
US201562250633P 2015-11-04 2015-11-04
PCT/IB2015/059515 WO2016097949A1 (en) 2014-12-17 2015-12-10 Formulations of a pi3k/mtor-inhibitor for intravenous administration

Publications (1)

Publication Number Publication Date
MX2017008072A true MX2017008072A (es) 2017-09-28

Family

ID=54937330

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008072A MX2017008072A (es) 2014-12-17 2015-12-10 Formulaciones de un inhibidor de pi3k/mtor para administracion intravenosa.

Country Status (25)

Country Link
US (2) US10172942B2 (es)
EP (1) EP3233054B1 (es)
JP (1) JP6420753B2 (es)
KR (1) KR102016822B1 (es)
CN (1) CN107205923B (es)
AU (1) AU2015365497B2 (es)
CA (1) CA2915199C (es)
CY (1) CY1124527T1 (es)
DK (1) DK3233054T3 (es)
ES (1) ES2881214T3 (es)
HR (1) HRP20211446T1 (es)
HU (1) HUE055928T2 (es)
IL (1) IL252158B (es)
LT (1) LT3233054T (es)
MX (1) MX2017008072A (es)
NZ (1) NZ731518A (es)
PL (1) PL3233054T3 (es)
PT (1) PT3233054T (es)
RS (1) RS62337B1 (es)
RU (1) RU2672875C1 (es)
SG (1) SG11201703826TA (es)
SI (1) SI3233054T1 (es)
TW (1) TWI660729B (es)
WO (1) WO2016097949A1 (es)
ZA (1) ZA201703764B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3672571B1 (en) 2017-08-25 2021-10-06 Pfizer Inc. Pharmaceutical aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
WO2019234632A1 (en) * 2018-06-07 2019-12-12 Pfizer Inc. Aqueous formulation comprising 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
CA3227191A1 (en) 2021-07-26 2023-02-02 Celcuity Inc. 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
WO2006125540A1 (en) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising a diaryl urea compound and a pi3, akt kinase or mtor inhibitors (rapamycins) for cancer treatment
US20080234262A1 (en) * 2007-03-21 2008-09-25 Wyeth Pyrazolopyrimidine analogs and their use as mtor kinase and pi3 kinase inhibitors
DE202008001253U1 (de) * 2008-01-28 2008-04-10 Mirror Image Ag Bildanzeigegerät
NZ588526A (en) * 2008-05-23 2012-08-31 Wyeth Llc Triazine compounds as pi3 kinase and mtor inhibitors
WO2009146406A1 (en) * 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
WO2010096619A1 (en) 2009-02-23 2010-08-26 Wyeth Llc Process, purification and crystallization of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea
US9757432B2 (en) * 2012-11-14 2017-09-12 Ohio State Innovation Foundation Materials and methods useful for treating glioblastorna
CA2903548A1 (en) * 2013-03-14 2014-09-25 Abraxis Bioscience, Llc Methods of treating bladder cancer
TWI693937B (zh) * 2014-03-14 2020-05-21 美商輝瑞大藥廠 包含治療劑之治療性奈米顆粒及其製造及使用方法

Also Published As

Publication number Publication date
US20190105390A1 (en) 2019-04-11
TW201632188A (zh) 2016-09-16
AU2015365497A1 (en) 2017-06-01
HRP20211446T1 (hr) 2021-12-24
SI3233054T1 (sl) 2021-11-30
CA2915199A1 (en) 2016-06-17
CA2915199C (en) 2018-11-06
NZ731518A (en) 2019-03-29
WO2016097949A1 (en) 2016-06-23
RS62337B1 (sr) 2021-10-29
ES2881214T3 (es) 2021-11-29
SG11201703826TA (en) 2017-07-28
EP3233054A1 (en) 2017-10-25
AU2015365497B2 (en) 2020-07-02
LT3233054T (lt) 2021-07-26
PT3233054T (pt) 2021-08-02
JP6420753B2 (ja) 2018-11-07
HUE055928T2 (hu) 2022-01-28
EP3233054B1 (en) 2021-06-30
TWI660729B (zh) 2019-06-01
CN107205923B (zh) 2021-03-05
IL252158A0 (en) 2017-07-31
CN107205923A (zh) 2017-09-26
ZA201703764B (en) 2020-11-25
BR112017010841A2 (pt) 2017-12-26
US10660959B2 (en) 2020-05-26
US10172942B2 (en) 2019-01-08
JP2016113461A (ja) 2016-06-23
RU2672875C1 (ru) 2018-11-20
KR20170082638A (ko) 2017-07-14
CY1124527T1 (el) 2022-07-22
DK3233054T3 (da) 2021-08-02
IL252158B (en) 2021-01-31
PL3233054T3 (pl) 2021-12-20
KR102016822B1 (ko) 2019-08-30
US20170360935A1 (en) 2017-12-21

Similar Documents

Publication Publication Date Title
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12018550120A1 (en) Steroid derivative fxr agonist
PH12016502081A1 (en) Compounds for treating spinal muscular atrophy
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
PH12016501355A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
PH12018500061A1 (en) Oxysterols and methods of use thereof
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
MY196243A (en) Dihydropyrimidine Compounds and Their Application In Pharmaceuticals
PH12016501794A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
MX2014012454A (es) Derivados de imidazotiadiazol como inhibidores del receptor 4 activado de proteasa (par4) para el tratamiento de agregacion plaquetaria.
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer&#39;s disease
NZ746825A (en) Oxysterols and methods of use thereof
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
MA39765A (fr) Formulation pharmaceutique d&#39;un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d&#39;utilisation
CY1124527T1 (el) Σκευασματα αναστολεα pi3k/mtor για ενδοφλεβια χορηγηση
PH12016502246B1 (en) Carboxamide derivatives
MX2018009458A (es) Derivado de sulfonamida heterociclico y medicina que contiene el mismo.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
MX2019006942A (es) Agonistas de receptores de oxitocina no peptidicos.
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
MX2019007360A (es) Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina.
MX2017013103A (es) Metodos para el tratamiento de trastornos cardiovasculares.
IN2014KO00191A (es)
TH167687B (th) ยาสำหรับป้องกันหรือรักษาภาวะท้องผูก